Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS), representing a revolutionary approach in the realm of liver cancer treatment over the last decade, can induce rapid future liver remnant (FLR) hypertrophy within a brief timeframe, offering renewed resection opportunities for patients with liver tumors (e.g., giant liver tumors) previously deemed unresectable because of an inadequate FLR volume and providing survival benefits to these patients [1]. Nonetheless, the mortality and complication rates are greater following the ALPPS procedure as compared to the conventional hepatic surgery. When initially implemented [2], the ALPPS procedure confers high rates of major complications (44%) and mortality (12%), hindering its widespread adoption and application.